HNPOLY(SZ:300630)2017-10-24 16:00Financial Performance - Operating revenue for the reporting period was ¥68,520,281.05, representing a 51.59% increase compared to the same period last year[8]. - Net profit attributable to shareholders of the listed company was ¥29,299,623.52, up 55.24% year-on-year[8]. - Basic earnings per share increased by 30.00% to ¥0.26 for the reporting period[8]. - Total operating revenue for the current period reached ¥68,520,281.05, an increase of 51.5% compared to ¥45,202,480.24 in the previous period[39]. - Net profit for the current period was ¥29,299,623.52, representing a significant increase of 55.4% from ¥18,873,301.36 in the previous period[40]. - Total revenue grew by 33.90% to CNY 198,605,748, reflecting strong business performance[17]. - Net profit for the period was CNY 60,522,372.34, representing a 45.9% increase from CNY 41,471,955.10 in the same period last year[48]. - Total profit for the period was CNY 66,422,510.87, compared to CNY 44,606,759.62, reflecting a growth of 48.9%[48]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥781,452,688.64, an increase of 77.72% compared to the end of the previous year[8]. - The company's total assets increased to ¥822,446,445.52, compared to ¥451,698,518.47 at the beginning of the period, marking an increase of 82%[36]. - The total liabilities decreased to RMB 108,526,981.76 from RMB 132,600,828.60, showing a reduction of about 18.1%[33]. - The total liabilities increased to ¥116,355,185.48 from ¥109,191,091.30, reflecting a growth of 6.3%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date reached ¥35,137,864.78, a significant increase of 456.27%[8]. - The cash inflow from operating activities totaled CNY 221,464,868.33, an increase of 19.25% compared to CNY 185,672,603.98 in the previous period[55]. - The net cash flow from operating activities was CNY 35,137,864.78, significantly up from CNY 6,316,690.89 in the same period last year[55]. - The cash inflow from financing activities amounted to CNY 326,782,863.45, a significant increase from CNY 43,105,700.00 in the previous period[58]. - The net cash flow from financing activities was CNY 282,747,197.09, compared to -CNY 9,831,322.17 in the same period last year[56]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,743[12]. - The largest shareholder, Fan Minhua, holds 35.16% of the shares, totaling 42,932,000 shares[12]. Investments and Expenses - The company’s investment payments increased by 853.12% to CNY 286,616,160, indicating a rise in external financial management[17]. - Total operating costs amounted to ¥37,394,616.22, up from ¥26,277,042.90, reflecting a year-over-year increase of 42.5%[39]. - Sales expenses increased to CNY 45,616,664.43, compared to CNY 34,777,434.06, marking a 31.2% rise[46]. - Management expenses rose to CNY 49,729,584.17 from CNY 33,467,005.09, an increase of 48.5%[46]. Government Grants and Approvals - The company received government grants totaling ¥1,369,527.13 during the reporting period[9]. - The company received approval for the drug "Azithromycin Injection" for domestic registration, enhancing its product portfolio[20]. - The company entered the national medical insurance directory with several products, expanding market access[21]. Other Financial Metrics - The weighted average return on net assets was 3.53%, down 48.00% compared to the previous year[8]. - The company reported no overdue commitments from controlling shareholders or related parties during the reporting period[24]. - There were no violations regarding external guarantees during the reporting period[26]. - The company did not experience any non-operating fund occupation by controlling shareholders or related parties[27].